Clinical Responses to Increasing Dose of Gefitinib or Erlotinib after Gefitinib Failure in Treatment for Advanced Non-small Cell Lung Cancer with Resistance to Gefitnib

JIANG Hao; ZHOU Tao; GAO Yajie; LIU Jiwei; DONG Yan

doi:10.3971/j.issn.1000-8578.2014.11.014

Cancer Research on Prevention and Treatment > 2014 > 41(11): 1223-1226. > DOI: 10.3971/j.issn.1000-8578.2014.11.014

JIANG Hao, ZHOU Tao, GAO Yajie, LIU Jiwei, DONG Yan. Clinical Responses to Increasing Dose of Gefitinib or Erlotinib after Gefitinib Failure in Treatment for Advanced Non-small Cell Lung Cancer with Resistance to Gefitnib[J]. Cancer Research on Prevention and Treatment, 2014, 41(11): 1223-1226. DOI: 10.3971/j.issn.1000-8578.2014.11.014

Citation:

PDF (2173 KB)

Clinical Responses to Increasing Dose of Gefitinib or Erlotinib after Gefitinib Failure in Treatment for Advanced Non-small Cell Lung Cancer with Resistance to Gefitnib

Department of Medical Oncology, The First Affiliated Hospital of Dalian Medical University,Dalian 116011,China

More Information

Received Date: September 08, 2013
Revised Date: November 12, 2013

Graphical Abstract

Abstract

Abstract

Objective To evaluate the efficacy of increasing dose of gefitinib or erlotinib after gefitinib failure in the treatment for advanced non-small cell lung cancer with resistance to routine dose of gefitnib. Methods A total of 40 patients with non-small cell lung cancer with resistance to routine dose of gefitinib after treatment for more than 6 months in The First Affiliated Hospital of Dalian Medical University from June 2007 to May 2012 were enrolled. They were equally randomized into two groups, one group treated with increasing dose of gefitinib, and the other group treated with erlotinib. The clinical efficacy and incidence of adverse reaction were comparatively analyzed. Results The efficacies of increasing dose of gefitinib group and erlotinib after gefitinib failure group were CR 0 vs. 0 case, PR 2 vs. 0 case, SD 11 vs. 13 cases, PD 7 vs. 7 cases. And the median progression free survival (PFS) were 9.1 and 3.0 months, respectively(P<0.05). The most common toxic effects were skin rash and diarrhea. Univariate and multivariate analysis revealed that increasing dose of geftinib or erlotinib after gefitinib failure were the independent prognosis factors. Conclusion Both increasing dose of gefitinib and erlotinib after gefitinib failure can be effective treatments for advanced non-small cell lung cancer to gefitnib responders, but the median PFS was significant prolonged by increasing dose of gefitinib, which appears more informative than replacement therapy with erlotinib in prognosis.
- Gefitinib,
- Erlotinib,
- Acquired drug-resistance,
- Non-small cell lung cancer

FullText(HTML)

References (16)

References

[1]	Kosaka T, Yarabe Y, Endoh H, et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib[J]. Clin Cancer Res, 20 06, 12(19): 5764-9.
[2]	Onitsuka T, Uramoto H, Nose N, et al . Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status[J]. Lung Cancer, 2010, 68(2): 198-203.
[3]	Pao W, Miller VA, Politi KA, et al . Acquired resistance of lung adenocarcinoma to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain[J]. PloS Med, 2005, 2( 3): e73.
[4]	Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall- cell lung cancer dependent on the epidermal growth factor receptor pathway[J]. Clin Lung Cancer, 2009, 10(4): 281-9.
[5]	Uramoto H, Iwata T, Onitsuka T, et al. Epithelial-mesenchymaltransition in EGFR-TKI acquired resistant lung adenocarcinoma[J]. Anticancer Res, 2010, 30(7): 2513-7.
[6]	Oh IJ, Ban HJ, Kim KS, et al. Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase Ⅱ study[J]. Lung Cancer, 2012, 77(1): 121-7.
[7]	Li JL, Hao XZ, Wang Y, et al. Clincal response to gefitinib retreatment of lung adenocarcinaoma patients who benefited from an initial gefitinib therapy: a retrospective analysis[J]. Zhongguo Fei Ai Za Zhi, 2012, 15(1): 44-8. [李峻岭, 郝学志, 王燕, 等. 初始易瑞沙治疗有效的晚期肺腺癌二次使用易瑞沙的疗效分析 [J] 中国肺癌杂志, 2012, 15(1): 44-8.]
[8]	Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types[J]. J Clin Oncol, 2002, 20(21): 4292-302.
[9]	Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies[J]. J Clin Oncol, 2001, 19(13): 3267-79.
[10]	Wong AS, Soong R , Seah SB, et al. Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer[J]. J Thorac Oncol, 20 08, 3(4): 400-4.
[11]	Vasile E, Tibaldi C, Chella A, et al . Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitnib[J]. J Thorac Oncol, 2008, 3(8): 91 2-4.
[12]	Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer[J]. N Engl J Med, 20 05, 353(2): 123-32.
[13]	Cho BC, Im CK, Park MS ,et al. Phase Ⅱ study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib[J]. J Clin Oncol, 2007, 25(18): 2528-33.
[14]	Kaira K，Naito T, Takahashi T, et a1．Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer[J]. Lung Cancer, 2010, 68(1): 99-104.
[15]	Yano T，Haro A，Shikada Y, et al. non-small cell lung cancer in never smokers as a representative ‘non-smoking-associated lung cancer’: epidemiology and clinical features[J]. Int J Clin Oncol, 20 11, 16(4): 287-93.
[16]	Hata A, Katakami N, Yoshioka H,et al. Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection[J]. Lung Cancer, 2011, 74(2): 268-73.

Cited By

Get Citation

PDF

XML

Article views (1507) PDF downloads (499)

Turn off MathJax

Article Contents

Abstract

References

Clinical Responses to Increasing Dose of Gefitinib or Erlotinib after Gefitinib Failure in Treatment for Advanced Non-small Cell Lung Cancer with Resistance to Gefitnib

Abstract

References

Catalog

Download Center

Links

Contact Us

Clinical Responses to Increasing Dose of Gefitinib or Erlotinib after Gefitinib Failure in Treatment for Advanced Non-small Cell Lung Cancer with Resistance to Gefitnib

Abstract

References

Catalog

Download Center

Links

Contact Us

Export File

Citation

Format

Content